Prostate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors such as Octamer Binding Factor 4 (OCT4)—plays a crucial role in therapeutic resistance and disease progression. OCT4, in coordination with SOX2 and NANOG, acts as a master regulator of stemness and is frequently upregulated in prostate cancer stem cells (PCSCs). This upregulation contributes to tumor initiation, metastasis, and resistance to both androgen deprivation therapy (ADT) and chemotherapy. In this review, we explore the role of OCT4 in mediating lineage plasticity in prostate cancer, with particular emphasis on its involvement in treatment resistance and neuroendocrine differentiation. We also examine therapeutic strategies aimed at targeting OCT4 directly, such as microRNA-mediated suppression, small-molecule inhibitors, and suicide gene therapy, as well as indirect approaches that modulate OCT4 expression via FGFR and NF-κB signaling pathways. While these strategies offer promising avenues, challenges such as adaptive resistance and the intricate signaling networks within PCSCs remain significant hurdles. A deeper understanding of the molecular mechanisms underlying OCT4-driven plasticity may pave the way for novel therapeutic approaches and improved outcomes in advanced prostate cancer.
HSPA5 (also known as GRP78/BiP) is a master regulator of the endoplasmic reticulum (ER) stress response and a key node in the proteostasis network. In neuroendocrine prostate cancer (NEPC), an aggressive, therapy‐refractory lineage that emerges under pressure from androgen receptor (AR) directed therapies, GRP78 is upregulated and co‐opted to maintain malignant cell survival. Beyond its canonical chaperone activity, GRP78 orchestrates adaptive unfolded protein response (UPR) signaling, buffers secretory stress, and stabilizes oncogenic proteomes. These functions collectively allow NEPC cells to evade apoptosis, tolerate proteotoxic stress, and resist next generation therapeutics. This review explores the emerging role of GRP78 as a therapeutic vulnerability in NEPC. We integrate evidence from proteostasis biology, lineage plasticity, and tumor microenvironment remodeling, and highlight experimental and clinical strategies targeting GRP78 directly (e.g., chaperone inhibitors, antibody therapy, peptide displacement) or indirectly through the proteostasis machinery (e.g., ERAD modulators, proteasome inhibitors, and UPR reprogramming). By reframing NEPC not only as a lineage plastic tumor but also as a proteostasis‐addicted state, we propose that GRP78 centered intervention is a promising route to break the current therapeutic ceiling.